Breaking News Instant updates and real-time market news.

GILD

Gilead

$72.64

-0.11 (-0.15%)

, CELG

Celgene

$99.64

1.14 (1.16%)

07:11
10/18/16
10/18
07:11
10/18/16
07:11

Jefferies sees 'attractive buying opportunities' in Biotech

The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.

GILD

Gilead

$72.64

-0.11 (-0.15%)

CELG

Celgene

$99.64

1.14 (1.16%)

MDCO

The Medicines Co.

$35.81

0.71 (2.02%)

ALKS

Alkermes

$42.37

0.07 (0.17%)

VRTX

Vertex

$80.50

1.27 (1.60%)

ALDR

Alder Biopharmaceuticals

$27.65

0.22 (0.80%)

CEMP

Cempra

$21.87

0.25 (1.16%)

RARE

Ultragenyx

$60.75

-0.82 (-1.33%)

IMMU

Immunomedics

$2.22

-0.07 (-3.06%)

  • 18

    Oct

  • 18

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 11

    Nov

  • 29

    Nov

  • 27

    Dec

  • 28

    Dec

GILD Gilead
$72.64

-0.11 (-0.15%)

10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
CELG Celgene
$99.64

1.14 (1.16%)

10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
LEER
10/17/16
NO CHANGE
LEER
Market Perform
Celgene data suggests viable drug, says Leerink
Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.
MDCO The Medicines Co.
$35.81

0.71 (2.02%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
GUGG
10/06/16
NO CHANGE
GUGG
The Medicines Co. weakness a buying opportunity, says Guggenheim
ALKS Alkermes
$42.37

0.07 (0.17%)

09/27/16
SBSH
09/27/16
NO CHANGE
Target $53
SBSH
Neutral
Alkermes price target raised to $53 from $44 at Citi
Citi analyst Liav Abraham raised her price target for Alkermes to $53 after the company hosted an investor event to overview the various aspects of Vivitrol. Alkermes' execution on a "unique commercial model," which targets the differing opioid addiction population needs on a state-by-state basis, is likely to drive robust volume growth going forward, particularly in the Medicaid patient population, Abraham tells investors in a research note. The analyst raised her estimates for Vivitrol but remains cautious on the FORWARD-5 data for ALKS 5461 due out in Q4. As such, Abraham keeps a Neutral rating on Alkermes.
09/27/16
JEFF
09/27/16
NO CHANGE
Target $62
JEFF
Buy
Alkermes sees significant room for Vivitrol upside, says Jefferies
Alkermes yesterday at its Vivitrol-focused event highlighted that the opioid treatment is still in the early stages of growth, Jefferies analyst Biren Amin tells investors in a research note. The company estimates that Vivitrol is currently capturing only 2% average market share and believes room for upside is significant, the analyst writes. He keeps a Buy rating on Alkermes with a $62 price target.
10/04/16
LEER
10/04/16
INITIATION
Target $57
LEER
Outperform
Alkermes reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Alkermes with an Outperform rating and $57 price target.
07/29/16
COWN
07/29/16
NO CHANGE
Target $60
COWN
Outperform
Alkermes weakness a buying opportunity, says Cowen
Cowen said the weakness in Alkermes is a buying opportunity as they believe the magnitude, sustainability, and impact of Vivitrol's growth is being meaningfully underestimated by the Street. Cowen reiterated its Outperform rating and $60 price target on Alkermes shares.
VRTX Vertex
$80.50

1.27 (1.60%)

10/06/16
JMPS
10/06/16
NO CHANGE
JMPS
Vertex Orkambi checks positive, says JMP Securities
After conducting checks with doctors, JMP Securities analyst Liisa Bayko says that uptake of Vertex's Orkambi drug among 6-11 year old children appears to be "rapid." Bayko expects Orkambi's market share in the age range to reach 70% within six months. She reiterates a $103 price target and Outperform rating on the stock.
10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
09/29/16
JMPS
09/29/16
NO CHANGE
JMPS
Vertex Orkambi approval should drive growth, says JMP Securities
JMP Securities analyst Liisa Bayko says that FDA approval of Vertex's Orkambi in the 6-11 year old population should enable the company to grow in Q4 after a temporary slowdown in Q3. However, the analyst expects Q4 Orkambi sales to come in at $285M, versus the consensus outlook of $295M. She keeps a $103 price target and Outperform rating on the shares.
10/17/16
PIPR
10/17/16
NO CHANGE
Target $129
PIPR
Overweight
Piper lays out reasons to buy Vertex with stock near 52-week lows
Piper Jaffray analyst Edward Tenthoff says shares of Vertex Pharmaceuticals are trading near 52-week lows following the company's "weak" Q3 guidance. The analyst believes investors should look past the outlook and he lays out six reasons for why to own the shares. The company will present Phase III ORKAMBI data on 58 homozygous F508del children aged 6-11 at the North American Cystic Fibrosis Conference being held from October 27-29, which formed the basis for label expansion, Tenthoff tells investors in a research note. Second, Vertex is launching ORKAMBI in homozygous F508del children, which should reaccelerate Q4 sales, the analyst contends. He also expects European reimbursement to come on-line in 2017, aiding revenue. The analyst sees revenue growth driving profitability and reiterates an Overweight rating on Vertex with a $129 price target. The stock closed Friday down $1.33 to $79.23.
ALDR Alder Biopharmaceuticals
$27.65

0.22 (0.80%)

09/30/16
BMUR
09/30/16
INITIATION
Target $45
BMUR
Buy
Alder Biopharmaceuticals assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage of Alder Biopharmaceuticals with a Buy rating and $45 price target. The company is poised to lead the migraine market, Yang tells investors in a research note.
09/13/16
JPMS
09/13/16
INITIATION
Target $40
JPMS
Overweight
Alder Biopharmaceuticals initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Alder Biopharmaceuticals with an Overweight rating and $40 price target. The analyst sees a "high probability of success" for ALD403, the company's treatment for the prevention of migraine in frequent episodic migraine and chronic migraine patients. She believes peak sales of the drug could be north of $1B.
06/21/16
JEFF
06/21/16
NO CHANGE
Target $61
JEFF
Buy
Alder Biopharmaceuticals weakness a buying opportunity, says Jefferies
Jefferies analyst Brian Abrahams believes weakness in Alder is due to concerns from a recent Cell publication citing theoretical risks of CV side effects from CGRP antagonists such as ALD403. The analyst said CV concerns have always been a theoretical risk with the CGRP class and there is nothing new in the Cell article. Abrahams views the weakness in Alder as a compelling buying opportunity and said today's downside is an overreaction. The analyst rates Alder a Buy with a $61 price target.
04/21/16
04/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alder Biopharmaceuticals (ALDR) resumed with an Outperform at Wells Fargo by analyst Jim Birchenough, who said the company's lead product in Phase 3 targets the large market of migraine prevention. 2. Tyson Foods (TSN) initiated with a Buy at Argus citing an expected benefit from strategic acquisitions and divestitures, as well as low commodity costs. 3. Adobe (ADBE) coverage assumed with a Neutral at Credit Suisse. 4. Intuit (INTU) initiated with a Neutral at Credit Suisse. 5. Endo (ENDP) initiated with an Outperform at JMP Securities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CEMP Cempra
$21.87

0.25 (1.16%)

06/24/16
NEED
06/24/16
NO CHANGE
Target $48
NEED
Buy
Needham expects 'moderate success' for Cempra Solithera
After attending the company's investor day, Needham analyst Alan Carr says that he expects Cempra to have moderate success in commercializing its Solithera independently, due to challenges for a biotech company in penetrating urgent and primary care. However, and despite believing that the commercial opportunity is probably larger in hands of Big Pharma, the analyst thinks the company's share price does not reflect what Cempra can accomplish independently. He reiterates a Buy rating and $48 price target on the shares.
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
07/12/16
JPMS
07/12/16
INITIATION
Target $31
JPMS
Overweight
Cempra initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Cempra with an Overweight rating and $31 price target. The analyst sees a "high probability of Fast Track US approval" by year-end for Solithera, a new antibiotic for community acquired pneumonia in adults. The analyst believes current share levels offer an attractive entry point.
09/13/16
RAJA
09/13/16
INITIATION
Target $32
RAJA
Outperform
Cempra initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated Cempra with an Outperform and a $32 price target. He believes Cempra's lead antibiotic Solithera holds a unique value proposition, the efficacy of a macrolide with improved barrier to resistance and a more favorable safety profile over fluoroquinolones. Raymond's 2025 end-market revenue estimate of $904 million assumes solely CAP usage, leaving other opportunities as call options.
RARE Ultragenyx
$60.75

-0.82 (-1.33%)

07/18/16
RHCO
07/18/16
NO CHANGE
RHCO
Ultragenyx mGUS drug likely to be approved by EU, says SunTrust
SunTrust says that the data for Ultragenyx's mGUS drug was "largely successful," with "very robust and consistent" efficacy on the primary endpoint. The firm says that the EU will very likely approve the drug, while U.S. approval "seems slightly questionable, but remains quite promising." The firm reiterates a $100 price target and Buy rating on the shares.
08/09/16
PIPR
08/09/16
NO CHANGE
Target $82
PIPR
Overweight
Ultragenyx price target raised to $82 from $70 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Ultragenyx to $82 following the company's Q2 results. Ultragenyx has multiple clinical and regulatory catalysts in the second half of 2016, Breazzano tells investors in a post-earnings research note. He reiterates an Overweight rating on the name.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/07/16
RHCO
09/07/16
NO CHANGE
RHCO
Ultragenyx data 'likely' to hit two primary endpoints, says SunTrust
SunTrust analyst Edward Nash says it's "likely" that Ultragenyx's KRN23 drug hit its phosphorus and rickets endpoints in a Phase II study. The analyst says he holds this view because of "the clear biology of the disease, the mechanism of the drug, and robust clinical data presented to date." Nash notes that the data is slated to be presented at a September 16-19 conference. He reiterates a $100 price target and Buy rating on the shares.
IMMU Immunomedics
$2.22

-0.07 (-3.06%)

10/06/16
JEFF
10/06/16
INITIATION
Target $5.5
JEFF
Buy
Immunomedics assumed with a Buy at Jefferies
Jefferies analyst Matthew Andrews assumed coverage of Immunomedics with a Buy rating and raised his price target for the shares to $5.50 from $5. IMMU-132's "promising results" in Triple Negative breast cancer sets the stage for a partnership deal in the coming months, Andrews tells investors in a research note.
06/21/16
WELS
06/21/16
DOWNGRADE
WELS
Market Perform
Immunomedics downgraded to Market Perform from Outperform at Wells Fargo
03/15/16
WELS
03/15/16
NO CHANGE
WELS
Immunomedics PANCRIT trial failure was expected, says Wells Fargo
After Immunomedics late yesterday announced that it's terminating its Phase 3 PANCRIT-1 trial, Wells Fargo says that this development was expected, given the trial's high clinical hurdle and invalidated target. Wells cut its price target on the stock to $3-$3.50 from $4-$4.50 in response to the news. However, the firm continues to believe that the company can find a partner for its IMMU132 drug, and it keeps an Outperform rating on the shares.
05/06/16
JEFF
05/06/16
UPGRADE
Target $5
JEFF
Buy
Immunomedics upgraded to Buy from Hold at Jefferies
Jefferies analyst Chris Howerton upgraded Immunomedics to Buy saying IMMU-132 continues to demonstrate impressive clinical data in solid tumors. The analyst sees a greater likelihood of Immunomedics securing a partner for the asset following recent data. He raised his price target for the shares to $5.00 from $1.50.

TODAY'S FREE FLY STORIES

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.